Thailand Unveils Draft Cannabis Law Targeting Medical Use, Shop Controls

Draft Law Restricts Cannabis to Medical-Only Framework

The draft legislation would eliminate recreational access entirely, confining cannabis use to patients with prescriptions issued by licensed medical practitioners. Possession or sale of cannabis products without valid medical documentation would revert to criminal penalties under Thailand's Narcotics Act, according to the bill's text. The measure marks a complete about-face from the June 2022 policy that allowed cultivation and sale with minimal regulatory oversight.

THC concentration limits? The draft doesn't specify them. That determination falls to a yet-to-be-formed regulatory body under the Ministry of Public Health. Industry observers note this ambiguity creates uncertainty for current operators who stock products ranging from low-THC wellness items to high-potency extracts. Public Health Minister Cholnan Srikaew, the bill's sponsor, stated the framework aims to prevent recreational misuse while preserving legitimate medical access.

Thailand's 2022 decriminalization sparked a retail boom concentrated in Bangkok, Phuket, and Chiang Mai, with an estimated 10,000 to 15,000 dispensaries opening within 18 months. Most operate as wellness shops or cafes selling flower, edibles, and topicals without prescription requirements. The draft law would force these businesses to either secure medical licensing or shut down.

Licensing and Operational Controls for Dispensaries

The bill mandates that all cannabis retail locations obtain a medical dispensary license from the Ministry of Public Health and employ at least one licensed pharmacist on-site during operating hours. Shops would be prohibited from selling to individuals under 20 years of age and barred from locating within 300 meters of schools or religious sites. Violations would carry fines up to 100,000 baht (approximately $2,800 USD) and potential license revocation.

Existing operators would have a 180-day grace period from the law's enactment to apply for licenses and comply with staffing and location requirements. Sources familiar with the draft indicate that many current shops lack the capital or pharmaceutical expertise to meet the pharmacist requirement, raising the prospect of mass closures. No grandfather clause exists for businesses operating under the 2022 framework.

The licensing timeline is tight, and the pharmacist mandate is a de facto barrier for most mom-and-pop shops that opened in the last two years.

The Ministry of Public Health would also gain authority to set product testing and labeling standards, including mandatory disclosure of cannabinoid profiles and contaminant screening. How would enforcement be resourced? The draft doesn't say. It's unclear whether local police or health inspectors would conduct compliance checks.

Political and Enforcement Uncertainty Ahead

The bill faces an uncertain path through Thailand's bicameral parliament, where coalition dynamics and public opinion on the 2022 decriminalization remain divided. Recent polling by Suan Dusit University showed 52% of respondents support restricting cannabis to medical use, while 38% favor maintaining the current open-access model. Opposition parties have signaled they may push for amendments that preserve limited recreational access or extend the transition period for existing businesses.

Even if the bill passes, enforcement will vary. Thailand's track record on cannabis policy implementation has been inconsistent. The 2022 delisting was announced with minimal regulatory infrastructure, leading to the current patchwork of local ordinances and ad-hoc enforcement. Observers expect provincial health offices to interpret the new law differently, particularly in tourist-heavy regions where cannabis shops generate tax revenue and foot traffic.

For full background on Thailand's evolving cannabis framework, see the CannIntel topic hub on Thailand Cannabis Regulation. The next legislative milestone is a parliamentary committee hearing scheduled for late July 2026, where industry groups and medical associations are expected to submit testimony. Until then, the draft's final form and its real-world impact on Thailand's sprawling cannabis retail sector remain unsettled.